BACKGROUND: The action of secretory phospholipase A(2) (sPLA(2)) on lipoproteins may render them more susceptible to oxidation, thereby promoting vascular inflammation and increasing cardiovascular risk. Patients with acute coronary syndrome face a high risk of early, recurrent cardiovascular events that is associated with biomarkers of inflammation, including sPLA(2). The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16, NCT01130246) tests the hypothesis that varespladib methyl, an inhibitor of several sPLA(2) isoforms with a causal role in atherosclerosis, reduces cardiovascular risk among patients with acute coronary syndromes. METHODS: Up to 6,500 patients with acute coronary syndrome will be randomized to receive treatment with varespladib methyl 500 mg daily or placebo for 16 weeks, in addition to background treatment with atorvastatin and other evidence-based therapies. The primary efficacy parameter is the combination of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for unstable angina with objective evidence of myocardial ischemia. Effects of varespladib methyl on lipid and inflammatory markers, in addition to safety and tolerability, will also be evaluated. CONCLUSION:sPLA(2) inhibition has the potential to exert a favorable effect on the artery wall. The VISTA-16 study will determine whether varespladib methyl has a beneficial impact on cardiovascular events in patients with an acute coronary syndrome.
RCT Entities:
BACKGROUND: The action of secretory phospholipase A(2) (sPLA(2)) on lipoproteins may render them more susceptible to oxidation, thereby promoting vascular inflammation and increasing cardiovascular risk. Patients with acute coronary syndrome face a high risk of early, recurrent cardiovascular events that is associated with biomarkers of inflammation, including sPLA(2). The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16, NCT01130246) tests the hypothesis that varespladib methyl, an inhibitor of several sPLA(2) isoforms with a causal role in atherosclerosis, reduces cardiovascular risk among patients with acute coronary syndromes. METHODS: Up to 6,500 patients with acute coronary syndrome will be randomized to receive treatment with varespladib methyl 500 mg daily or placebo for 16 weeks, in addition to background treatment with atorvastatin and other evidence-based therapies. The primary efficacy parameter is the combination of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for unstable angina with objective evidence of myocardial ischemia. Effects of varespladib methyl on lipid and inflammatory markers, in addition to safety and tolerability, will also be evaluated. CONCLUSION:sPLA(2) inhibition has the potential to exert a favorable effect on the artery wall. The VISTA-16 study will determine whether varespladib methyl has a beneficial impact on cardiovascular events in patients with an acute coronary syndrome.
Authors: Pier Woudstra; Peter Damman; Wichert J Kuijt; Wouter J Kikkert; Maik J Grundeken; Peter M van Brussel; An K Stroobants; Jan P van Straalen; Johan C Fischer; Karel T Koch; José P S Henriques; Jan J Piek; Jan G P Tijssen; Robbert J de Winter Journal: PLoS One Date: 2014-05-01 Impact factor: 3.240
Authors: Ricardo C Ferreira; Daniel F Freitag; Antony J Cutler; Joanna M M Howson; Daniel B Rainbow; Deborah J Smyth; Stephen Kaptoge; Pamela Clarke; Charlotte Boreham; Richard M Coulson; Marcin L Pekalski; Wei-Min Chen; Suna Onengut-Gumuscu; Stephen S Rich; Adam S Butterworth; Anders Malarstig; John Danesh; John A Todd Journal: PLoS Genet Date: 2013-04-04 Impact factor: 5.917
Authors: Michael V Holmes; Tabassome Simon; Holly J Exeter; Lasse Folkersen; Folkert W Asselbergs; Montse Guardiola; Jackie A Cooper; Jutta Palmen; Jaroslav A Hubacek; Kathryn F Carruthers; Benjamin D Horne; Kimberly D Brunisholz; Jessica L Mega; Erik P A van Iperen; Mingyao Li; Maarten Leusink; Stella Trompet; Jeffrey J W Verschuren; G Kees Hovingh; Abbas Dehghan; Christopher P Nelson; Salma Kotti; Nicolas Danchin; Markus Scholz; Christiane L Haase; Dietrich Rothenbacher; Daniel I Swerdlow; Karoline B Kuchenbaecker; Eleonora Staines-Urias; Anuj Goel; Ferdinand van 't Hooft; Karl Gertow; Ulf de Faire; Andrie G Panayiotou; Elena Tremoli; Damiano Baldassarre; Fabrizio Veglia; Lesca M Holdt; Frank Beutner; Ron T Gansevoort; Gerjan J Navis; Irene Mateo Leach; Lutz P Breitling; Hermann Brenner; Joachim Thiery; Dhayana Dallmeier; Anders Franco-Cereceda; Jolanda M A Boer; Jeffrey W Stephens; Marten H Hofker; Alain Tedgui; Albert Hofman; André G Uitterlinden; Vera Adamkova; Jan Pitha; N Charlotte Onland-Moret; Maarten J Cramer; Hendrik M Nathoe; Wilko Spiering; Olaf H Klungel; Meena Kumari; Peter H Whincup; David A Morrow; Peter S Braund; Alistair S Hall; Anders G Olsson; Pieter A Doevendans; Mieke D Trip; Martin D Tobin; Anders Hamsten; Hugh Watkins; Wolfgang Koenig; Andrew N Nicolaides; Daniel Teupser; Ian N M Day; John F Carlquist; Tom R Gaunt; Ian Ford; Naveed Sattar; Sotirios Tsimikas; Gregory G Schwartz; Debbie A Lawlor; Richard W Morris; Manjinder S Sandhu; Rudolf Poledne; Anke H Maitland-van der Zee; Kay-Tee Khaw; Brendan J Keating; Pim van der Harst; Jackie F Price; Shamir R Mehta; Salim Yusuf; Jaqueline C M Witteman; Oscar H Franco; J Wouter Jukema; Peter de Knijff; Anne Tybjaerg-Hansen; Daniel J Rader; Martin Farrall; Nilesh J Samani; Mika Kivimaki; Keith A A Fox; Steve E Humphries; Jeffrey L Anderson; S Matthijs Boekholdt; Tom M Palmer; Per Eriksson; Guillaume Paré; Aroon D Hingorani; Marc S Sabatine; Ziad Mallat; Juan P Casas; Philippa J Talmud Journal: J Am Coll Cardiol Date: 2013-07-31 Impact factor: 24.094
Authors: Chunfang Xie; Laura-Oana Albulescu; Kristina B M Still; Julien Slagboom; Yumei Zhao; Zhengjin Jiang; Govert W Somsen; Freek J Vonk; Nicholas R Casewell; Jeroen Kool Journal: Biomedicines Date: 2020-06-17